Xenon Pharmaceuticals Inc... (XENE)
39.41
0.91 (2.36%)
At close: Feb 20, 2025, 3:59 PM
39.38
-0.06%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 37.2 |
| Market Cap | 3.00B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.81 |
| PE Ratio (ttm) | -14.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 40.99 |
| Volume | 264,028 |
| Avg. Volume (20D) | 409,779 |
| Open | 38.43 |
| Previous Close | 38.50 |
| Day's Range | 38.34 - 39.54 |
| 52-Week Range | 35.53 - 50.99 |
| Beta | undefined |
About XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment o...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 5, 2014
Employees 251
Stock Exchange NASDAQ
Ticker Symbol XENE
Website https://www.xenon-pharma.com
Analyst Forecast
According to 8 analyst ratings, the average rating for XENE stock is "Buy." The 12-month stock price forecast is $57.5, which is an increase of 45.92% from the latest price.
Buy 87.50%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Xenon Pharmaceuticals Inc. is scheduled to release its earnings on Mar 3, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
